Aakaar Medical Technologies Limited has announced the schedule for its 13th Annual General Meeting (AGM), which is set to be conducted via video conferencing. The meeting is scheduled for Tuesday, June 30, 2026, at 3:00 P.M. IST.

In compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has fixed specific dates to determine shareholder eligibility for the proceedings. These dates are crucial for shareholders to ensure their participation and entitlement to receive the official notice.

The record date for determining shareholders entitled to receive the Notice of the AGM has been fixed as Friday, May 29, 2026. Additionally, the company established a cut-off date for determining eligibility for remote e-voting and e-voting during the AGM as Tuesday, June 23, 2026.

The following table outlines the key dates announced by the company:

Shareholders are advised to take note of these dates to facilitate their participation in the upcoming annual general meeting.

Aakaar Medical Technologies has announced its entry into the manufacturing of Aesthetics Devices, following a decision taken by its Board of Directors in their meeting held on May 15, 2026. The development was disclosed to the National Stock Exchange of India Limited under Regulation 30(4)(i)(d) read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in accordance with the company's Policy on Determination of Materiality of Events and Information.

New Manufacturing Facility in Pune

The company has decided to lease a premises in Pune for the purpose of contract manufacturing of Aesthetics Devices. This marks a new business vertical for Aakaar Medical Technologies, expanding its product portfolio into the aesthetics segment. The arrangement involves no special rights such as the right to appoint directors, first right to share subscription in case of issuance of shares, or the right to restrict any change in capital structure.

The key details of the disclosure, as filed under Annexure A pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, are summarised below:

Regulatory Compliance and Disclosure

The disclosure was made by Company Secretary and Compliance Officer Anoopkumar Pillai on behalf of Aakaar Medical Technologies. The filing confirms that the transaction does not constitute a related party transaction and that the parties involved bear no relationship to the promoter, promoter group, or group companies. No shares are being issued, and no loan agreements are associated with this arrangement.

The announcement underscores the company's commitment to regulatory transparency as it pursues this new manufacturing initiative in the medical aesthetics space.